Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
42 days after the first vaccine dose •To demonstrate the non-inferiority of the MenACWY-TT conjugate vaccine when compared to Meningitec, the licensed conjugate vaccine for N. meningitidis serogroup C, in terms of serogroup C serum bactericidal antibodies (rSBA-MenC). •To demonstrate the immunogenicity induced by the MenACWY-TT conjugate vaccine for N. meningitidis serogroups A, W-135, and Y in terms of bactericidal antibodies to N. meningitidis serogroups A, W-135, and Y. •To demonstrate the non-inferiority of MenACWY-TT conjugate vaccine co-administered with MMRV compared to MenACWY-TT conjugate vaccine alone in terms of bactericidal antibodies to N. meningitidis serogroups A, C, W-135, and Y. •To demonstrate the non-inferiority of the immunogenicity of the first dose of MMRV vaccine co-administered with MenACWY-TT conjugate vaccine compared to the first dose of MMRV vaccine alone with respect to anti-measles, anti-mumps, anti-rubella, and anti-varicella seroconversion rates.
Inclusion criteria
- One dose primary immunization against Neisseria meningitidis serogroups A, C, W-135, and Y when given alone or when co-administered with a first dose of Priorix-Tetra in healthy children aged 12 to 23 months